Mathias Witzens-Harig

Scientific category: IMMUNOBIOLOGY Corresponding Author:

Kai, Gerhard Moldenhauer, Nathalie Fiegler, 2017 .

Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer

Michael Thomas, Cleo-Aron Weis, Claus Peter Heussel, 2020, Cancers.

The CCND1 870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma

Asta Försti, Lewin Eisele, Hartmut Goldschmidt, 2013, Nature Genetics.

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Nibedita Bandyopadhyay, Martin Dreyling, Mathias Witzens-Harig, 2016, The Lancet.

Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.

Michael Hallek, Ulrich Keller, Mathias Witzens-Harig, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.